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HIGHLIGHTS 
 Compared to Survey I1, more oncology professionals were at risk of poor well-being 
(33% vs 25%) and burnout (49% vs 38%).
 Job performance since COVID-19 (JP-CV) has improved from 34% to 51%. 
 About 1 in 5 who tested positive for COVID-19 felt they had not been given adequate 
time to recover prior to return to work.
 39% expresse  concerns that COVID-19 would have a negative impact on their career 
development or training.
 More than two-thirds revealed that COVID-19 had changed their outlook on work-
personal life balance. 
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ABSTRACT 
Background
The COVID-19 pandemic has resulted in significant changes to professional and personal lives 
of oncology professionals globally. The ESMO Resilience Task Force collaboration aimed to 
provide contemporaneous reports on the impact of COVID-19 on the lived experiences and 
well-being in oncology.
Methods
This online anonymous survey (July-August 2020) is the second of a series of global surveys 
launched during the course of the pandemic. Longitudinal key outcome measures including 
well-being/distress (expanded Well-being Index (eWBI – 9 items)), burnout (1 item from 
eWBI) and job performance since COVID-19 (JP-CV) were tracked.
Results
942 participants from 99 countries were included for final analysis: 58% (n=544) from Europe, 
52% (n=485) female, 43% (n=409) 40 years old, and 36% (n=343) of non-white ethnicity. In ≤
July/August 2020, 60% (n=525) continued to report a change in professional duties compared 
to pre-COVID-19 era. The proportion of participants at risk of poor well-being (33%, n=310) 
and reported feeling burnout (49%, n=460) had increased significantly compared to April/May 
2020 (25% and 38%, respectively; p<0.001), despite improved JP-CV (34% vs 51%; p<0.001). 
Of those who had been tested for COVID-19, 8% (n=39/484) tested positive; 18% (n=7/39) 
felt they had not been given adequate time to recover prior to return to work. Since the 
pandemic, 39% (n=353/908) had expressed concerns that COVID-19 would have a negative 
impact on their career development or training and 40% (n=366/917) felt that their job 
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security had been compromised. More than two-thirds (n=608/879) revealed that COVID-19 
has changed their outlook on their work-personal life balance. 
Conclusion
The COVID-19 pandemic continues to impact the well-being of oncology professionals globally 
with significantly more in distress and feeling burnout compared to the first wave. Collective 
efforts from both national and international communities addressing support and coping 
strategies will be crucial as we recover from the COVID-19 crisis. In particular, an action plan 
should also be devised to tackle concerns raised regarding the negative impact of COVID-19 
on career development, training, and job security.
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INTRODUCTION
The COVID-19 pandemic and our response to it continues to shape lives globally. Many 
healthcare workers have seen both their professional and personal lives significantly 
impacted, with the oncology community being no exception. The ESMO (European Society 
for Medical Oncology) Resilience Task Force, established in December 2019, launched a 
longitudinal series of global surveys in April/May 2020 (Survey I) and July/August 2020 (Survey 
II) to evaluate the challenges posed by COVID-19 on the daily practice and well-being of 
oncology professionals.1 Preliminary results from our survey series indicate that COVID-19 
has had a significant impact on the oncology workforce. Of the 1520 survey I participants, 
25% were at risk of distress, 38% reported feeling burnout, and 66% reported not being able 
to perform their job compared with the pre-COVID era.1 A higher mortality rate from COVID-
19 in individual countries correlated with poorer well-being. Individual psychological 
resilience and changes in work hours were also consistent predictors. This is in keeping with 
emerging trends in several studies reporting increased psychological distress and emotional 
exhaustion amongst healthcare workers, particularly with increased job demands, during this 
pandemic.2-5 Concerningly, amongst the 272 participants who completed both surveys I and 
II, a significant increase in risk of distress/poor well-being (22% versus 31%) and burnout (35% 
versus 49%) was already noted over a 3-month period during the pandemic despite 
improvements in job performance.1  
Here, we present the complete analysis of responses from all 942 participants of survey II of 
our global survey series.
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METHODS
Survey design
Survey II (open from 16 July to 5 August 2020) formed part of the series of online global 
surveys designed by the ESMO Resilience Task Force, in collaboration with ESMO Young 
Oncologists Committee, ESMO Women for Oncology Committee, ESMO Leaders Generation 
Programme Alumni members, and the OncoAlert Network. The programme of work including 
this current survey was approved by the ESMO Executive Board. Participants were invited 
predominantly through ESMO membership emails, and open access to the survey, hosted on 
the Qualtrics platform, was also available to both members and non-members through the 
ESMO website and social media channels. Participation was voluntary and anonymous.
Survey measures
Key outcomes of interest including well-being, burnout and job performance since COVID-19 
(JP-CV) were longitudinally monitored as per Survey I.1 In brief, a calculated cumulative score 
of ≥4 on the validated expanded Well-being Index (eWBI) 9-item screening tool is considered 
at risk of poor well-being or distress.6 A ‘yes’ response to th  single item from eWBI,1,7 ‘have 
you felt burned out from your work?’ was used as a surrogate for self-reported burnout 
amongst participants. JP-CV score of ≥3.5 was arbitrarily categorised as favourable JP-CV.1   
In addition, psychological resilience (single item 9-point bipolar scale, C. Hardy (unpublished 
data)), coping strategies, COVID-19-related job changes, perceptions of value and support, 
working environment, and changes to lifestyle were recorded. We also included 
contemporaneous questions relevant to participants’ experiences during this period of the 
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pandemic such as personal experience of COVID-19, perceptions of their career development 
and/or training and job security, and general outlook in life.
Statistical analysis
Key outcome variables including eWBI, burnout, JP-CV and psychological resilience were 
longitudinally compared to the results from Survey 11 to determine any changes over time. 
Descriptive data were presented as median (interquartile range, IQR) or mean±standard 
deviation (SD), and proportions were expressed as a percentage. Chi-square analysis was 
used to compare categorical variables and paired or unpaired t-test were used to analyse 
continuous variables; p-values were two-tailed and were considered significant if <0.05. 
Participants who completed 33% of the survey (completion of survey beyond personal ≥
demographic profile and with the four key outcome variables above recorded) were included 
in the final analysis. All statistical analyses were performed using SPSS V.26.0 and data 
represented using GraphPad Prism V9.0. 
RESULTS
Participant demographics
A total of 942 participants from 99 countries who completed 33% of the online survey ≥
(n=816 (86.6%) with 100% completion) were included in the final analysis. By July/August 
2020, most participants (n=826, 87.7%) had experienced some form of lockdown/restriction 
in their region of work and only a minority (n=44, 4.7%) were working in a ‘COVID-19-free’ 
country. Table 1 summarises the key demographic characteristics of the participants.
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During the time of Survey II, responses were predominantly from Europe (n=544, 57.7%) with 
the highest representation from those working in medical oncology (n=634, 67.3%) and those 
working in a general hospital (n=421, 44.1%) or tertiary cancer centre (n=368, 39.1%) (Table 
1). More than half of the participants were female (n=485, 51.5%), over 40 years old (n=533, 
56.6%), and of white ethnicity (n=587, 62.3%) (Table 1). About 1 in 5 (n=184) were trainees, 
and amongst those who were fully-trained oncologists, majority (n=437, 57.7%) had more 
than 10 years of experience in the field (Table 1).
Changes in professional duties since COVID-19
In July/August 2020, the majority of participants (n=525/869, 60.4%) were still reporting a 
change in their professional duties when compared to pre-COVID-19 era. The nature of 
changes in professional duties are outlined in Table 2. There was a marked increase in remote 
consultations (n=472/528, 89.4%), virtual multidisciplinary team/tumour board meetings 
(n=450/534, 84.3%), remote meetings (n=506/550, 92.0%), and COVID-19-related research 
activity (n=202/344, 58.7%) (Table 2). In particular, more than a third (n=221/575, 38.4%) had 
reported an increase in overall hours of work in comparison to pre-COVID-19 work schedule 
and about two-thirds (n=362/549, 65.9%) had reported an increase in hours working from 
home (Table 2 and Supplementary Figure S1). The majority were still experiencing a reduction 
in clinical trials (n=320/486, 65.8%) and other research (n=275/493, 55.8%) activities (Table 
2). Overall, however, the self-reported job performance since COVID-19 (JP-CV) had increased 
compared to April/May 2020; the proportion of those with JP-CV score ≥3.5 had increased 
from 34.4% (n=523/1520) to 50.9% (n=444/873) in July/August 2020, p<0.001.
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Personal experience of COVID-19
More than 1 in 5 participants (n=181/854, 21.2%) disclosed that their current circumstance 
or underlying comorbidities would put them at an increased personal risk of being seriously 
ill from COVID-19 (Table 3). Amongst those who had been tested (n=484), 39 participants 
(8.1%) had had COVID-19. Most underwent isolation or sick leave due to COVID-19 symptoms 
(n=25/39, 64.1%). Within this subgroup who had had COVID-19, the median duration of 
symptomatic COVID-19 was 8.5 days (n=22, range 1 to 42 days). About 1 in 5 (n=7/39) did not 
feel they were given appropriate time to recover and 11 participants (28.2%) did not feel 
completely recovered upon return to work. Notably, 14.8% (n=126/849) revealed that they 
have had a colleague who has died from COVID-19. 
The impact of COVID-19 on perception of career development and training
As the COVID-19 pandemic evolved, we questioned participants regarding their outlook in 
their personal and professional life. Alarmingly, 38.9% (n=353/908) had expressed concerns 
that the pandemic would have a negative impact on their career development and/or 
training, and 39.9% (n=366/917) felt that COVID-19 has negatively impacted on their job 
security (Figure 1a-1b). Majority (n=650/861, 75.5%) were also concerned about the negative 
impact on international fellowship opportunities (Figure 1c). 
The feeling of loss of control and helplessness during the COVID-19 crisis
During the course of the COVID-19 pandemic, more than a third of participants (n=339/859, 
37.5%) had experienced a loss of control or felt helpless in meeting the expectations of their 
patients (Figure 1d). Similarly, more than a quarter also expressed the perception of loss of 
control or helplessness in meeting the expectations of their colleagues, supervisor and/or 
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employer (Figure 1d). Additionally, more than half feeling loss of control or helpless with 
regards to pursuing their career goal (n=458/866, 52.9%) (Figure 1e).
On personal reflection, for more than two-thirds of participants (n=608/879, 69.2%), the 
COVID-19 pandemic had changed their outlook on work-personal life balance (Figure 1f). A 
majority (n=612/870, 70.3%) would like to dedicate more time to their personal life, however 
only less than a third (n=271/863, 31.4%) felt that a change in their work-personal life balance 
could be easily achievable (Figure 1f). Currently, 43.0% (n=405/942) of participants did not 
feel that their work schedule leaves them enough time for their personal and family life.
Well-being and burnout
Among participants, 32.9% (n=310) were at risk of poor well-being (eWBI score ≥4) and 48.8% 
(n=460) reported feeling burnout compared to 25% (p<0.001) and 38% (p<0.001) of the 1520 
participants surveyed in April/May 2020, respectively. The magnitude of increase in both of 
these outcome measures were also seen within the subgroup of 272 participants who 
responded to both Surveys I and II.1
Resilience, well-being support and coping strategies
Collectively, there was no difference in psychological resilience amongst participants in both 
Surveys I and II: mean score 6.4±1.9 versus 6.4±2.0, respectively (p=0.82). Access to well-
being support services was available to less than half of the participants (n=421, 44.7%). 
Supplementary Table S1 summarises a variety of well-being support services and coping 
strategies commonly used by participants during this COVID-19 pandemic. Importantly, 
majority continued to feel well-supported by their friends and/or family (n=729/835, 87.3%) 
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and by their colleagues at work (n=648/835, 77.6%). In Survey II, 63.9% (n=537/841) and 
53.7% (n=452/841) expressed feeling valued by the public and their work organisation, 
respectively.
DISCUSSION
Within a three-month period (April/May 2020 to July/August 2020) at the beginning of the 
COVID-19 pandemic, Survey II has already highlighted a significant increase in risk of poor 
well-being (33% versus 25%) and burnout (49% versus 38%). This is despite significant 
improvement in self-reported job performance over the same time period. This is an alarming 
finding and suggests that although oncology professionals may be adapting effectively to 
change, they continue to be at increasing risk of distress.  
Survey II highlights a number of factors in the current climate that may be contributing to this 
deterioration in well-being. Most participants (n=826, 88%) had experienced some form of 
lockdown/restriction in their region of work. In addition to such significant imposed changes 
in their personal lives, around 60% of participants continued to report a change in 
professional duties. Some of these, such as an increase in remote consultations and virtual 
meetings, have their advantages.4,8 However, nearly 40% had reported an overall increase in 
their work hours compared to their pre-COVID-19 schedule (also see supplementary Figure 
S1). The majority had also experienced a reduction in clinical trials and traditional oncology-
focused research activity. These are an integral part of working life in oncology and often a 
source of meaning. Increased working hours and a reduction in activities that are 
professionally meaningful are well-known risk factors for burnout.9  
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More Survey II participants had reported a close personal experience with COVID-19 either 
by testing positive for SARS-CoV-2 (8%) or requiring self-isolation or sick leave due to COVID-
19 symptoms (18%). Worryingly, nearly 15% had had a colleague die from COVID-19. 
Furthermore, one in five participants also disclosed that they had underlying comorbidities 
that would put them at an increased personal risk of being seriously ill from COVID-19. Of 
those who have had COVID-19, the median duration of symptomatic COVID-19 was 8.5 days 
but notably, the range for this was broad, from 1 to 42 days. Importantly, 18% feel that they 
did not have enough time to recover from illness and close to 30% did not feel completely 
recovered from illness prior to returning to work. Given the reports of potential substantial 
long-term morbidity associated with COVID-19 (‘long COVID’),10,11 this is particular cause for 
concern and will require careful ongoing monitoring.  
A substantial number of participants had expressed significant uncertainty about the future 
of their professional lives. Approximately 40% felt that COVID-19 would have a negative 
impact on their career development, training, and job security. Over 75% were also concerned 
about the negative impact on international fellowship opportunities, an important facet of 
professional development in oncology. This ties in with a recurrent concern expressed by 
participants of loss of control or helplessness in achieving their career goals (53%).  
Anxiety and fear amongst healthcare workers can be associated with higher rates of burnout.4  
Delays in patient care and treatment have been a substantial source of distress in other 
studies for oncology practitioners.4 These are understandable responses in a climate of crisis 
and prolonged uncertainty as has been noted during previous pandemics.3 Overall, our 
findings highlight significantly increasing rates of distress and burnout. The rapidity in the 
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rates of increased burnout distress within a three-month period is a notable finding and a 
major cause for concern. This may be an ominous harbinger of what lies ahead in ongoing 
and future ESMO Resilience Task Force surveys which have coincided with periods of 
extended lockdown and further ‘waves’ of cases and deaths. The time for action therefore is 
now. Survey II already highlights useful areas of support and immediate intervention that may 
be of benefit to oncology professionals globally.
Firstly, there are significant measures organisations can take to improve the well-being of 
staff. Enhanced mentorship of practitioners to ensure ongoing support for career 
development and planning as well as sourcing of suitable professional opportunities. Despite 
the focus on the COVID-19 response, ongoing investment in oncology-focused research and 
clinical trials need to continue, including fostering transnational fellowship opportunities.12-14 
More particularly, despite additional pressures, the accessible and continued support of 
supervisors for trainees is even more paramount. A routinely scheduled time for a “team 
huddle” or debriefing program for all staff in the emergency department has been shown to 
be well-received and beneficial for both junior and senior team members alike during these 
challenging times.15
Secondly, the personal impact of COVID-19 on the health and well-being of oncology 
professionals have been emphasised by the findings of Survey II. Ensuring safe work 
conditions, including access to personal protective equipment, COVID-19 testing, and 
vaccination are paramount.16,17 Also ensuring the provision of adequate sick leave for self-
isolation and recovery from symptoms should be mandated, as well as, supporting “shielding” 
practices to ensure those with comorbidities are in lower risk activities or exposure sites. The 
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number of participants who had experienced the death of a colleague also raises the need for 
adequate access to bereavement support. Participants had similarly highlighted that access 
to counselling/psychological services and other resources to promote well-being and coping 
strategies would be welcomed.  
Of importance for future oncology workforce planning, the majority of participants had 
reported changing their outlook on their work-personal life balance as a result of the COVID-
19 pandemic, including a desire for better work-life balance. The majority supported flexible 
working hours, including working from home. Ensuring work hours and workplace flexibility 
as well as encouraging staff to take annual leave are important organisational leadership 
measures.
Although we focus on the solutions necessary, participants had likewise shared a number of 
strategies they were already using to cope currently, such as tapping into personal and 
professional support networks, employing strategies such as mindfulness meditation and 
smartphone apps, and feeling valued by their organisation. Supportive interventions need to 
be multi-faceted with workplaces, and national and international oncology societies such as 
ESMO and American Society of Clinical Oncology (ASCO)18 playing a key facilitative role.
A significant strength of Survey II is our substantial participant size of 942 and scope with 99 
countries being represented. Over a third of our participants were from Germany, India, 
United Kingdom, Italy, Spain and Brazil – a number of these countries have borne the brunt 
of global morbidity and mortality, which makes their representation in this survey important 
and notable. There was even representation across the genders (52% female), as well as 
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young oncologists (43%), current trainees (20%), and those of non-white ethnicity (36%), as 
our previous research and that of other groups have found these groups to be at particularly 
heightened risk of experiencing burnout.1,19,20 More than a third of participants were of non-
white ethnicity, which is again an important aspect as studies have shown that those of black 
or minority ethnic backgrounds are at higher risk of complications from COVID-19.21  
A key factor in the well-being of all during these times has been the response of individual 
nations to this pandemic. Only a small minority of participants in our survey (4%) were from 
‘COVID-19-free’ nations which reflects their smaller population size. Our ability to discern the 
difference in well-being between those in higher prevalence versus COVID-19-free regions 
has been limited by this small sample size. This is also a cross-sectional, observational study 
which limits our ability to infer causality. However, to our knowledge, this is the only survey 
series in oncology addressing well-being systematically and longitudinally throughout the 
course of the COVID-19 pandemic. A substantially larger dataset from the recently closed 
Survey III and more detailed longitudinal statistical analyses of factors associated with well-
being, burnout and distress will provide further insight into navigating recovery plans going 
forwards. The collective experience shared by participants completing this survey series, and 
the ongoing work of the ESMO Resilience Taskforce and other organisations will help direct 
efforts to support the well-being of oncology professionals globally.
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TABLE CAPTIONS 
Table 1 Participant demographics (n=942).
Table 2 Overview of the changes in professional duties since the COVID-19 outbreak 
(n=942).
Table 3 Participants’ personal experience of COVID-19 (n=854)
FIGURE CAPTIONS 
Figure 1 The impact of COVID-19 on (a- c) the perception of career development and/or 
training opportunities (n=925), (d-e) sense of control (n=892), and (f) future 
outlook in work/personal life balance (n=892).
Figure 2 Summary of key suggestions from participants on well-being and coping 
strategies which might be helpful as part of the COVID-19 recovery plan 
(n=827). 
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SUPPLEMENTARY DATA
Table S1 Well-being support and coping strategies amongst participants during the 
COVID-19 crisis (n=942).
Figure S1 Comparison of self-reported working hours amongst participants during 
Survey I (16 April to 3 May 2020) (n=1520) and Survey II (16 July to 5 August 
2020) (n=872).
Figure S2 Working environment during the COVID-19 pandemic in July/August 2020 
(n=846).



































































   ≤40




   Female 
   Male





   White 
   Asian (East/Southeast)
   Asian (South)
   Hispanic
   Arab 
   Mixed 
   Black 
   Other











   Yes




   Yes
   No
562 (59.7%)
380 (40.3%)
Median number of children, n=562 2 (range 1-8)
Age of children, n=562
   Pre-school
   Primary school
   Secondary school
   Adult (living at home)







   Europeb
        Central Europe 
        Southwestern Europe
        Northern Europe and British Isles 
        Southeastern Europe 
        Western Europe
        Eastern Europe
   Asia 
   North America 
   South America 
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   Oceania
   Prefer not to say
23 (2.4%)
2 (0.2%)
Primary place of work
   General hospital 
   Cancer centre
   Private outpatient clinic
   Pharmaceutical/technology company
   Healthcare organisation








   Medical oncology 
   Clinical oncology
   Haemato-oncology 
   Palliative care 
   Radiation oncology
   Laboratory-based researcher/scientist
   Surgical oncology
   Nursing











   Yes
   No
184 (19.5%)
758 (80.5%)
Duration of training completed (years), n=184
   <2
   2-5




Post-training oncology experience (years), n=758
   <5 
   5-10 
   >10






   Yes
   No
854 (90.7%)
88 (9.3%)
aCountries most represented were Germany (n=85), India (n=67), United Kingdom (n=62), Italy (n=56), Spain (n=44) and Brazil (n=34).
bCentral Europe – Austria, Czech Republic, Germany, Hungary, Poland, Romania, Slovakia, Slovenia, Switzerland; Southwestern Europe – 
Italy, Portugal, Spain; Northern Europe and the British Isles – Denmark, Finland, Norway, Republic of Ireland, Sweden, United Kingdom; 
Southeastern Europe – Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Greece, Israel, Kosovo, Montenegro, North Macedonia, 
Serbia, Turkey; Western Europe – Belgium, France, Luxembourg, The Netherlands; and Eastern Europe – Belarus, Estonia, Georgia, Latvia, 
Lithuania, Moldova, Russian Federation, Ukraine).
cNote that some participants have selected 2 or more specialties within their job role, and proportion of representation is summarised as 
such.
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Table 2
Number (%)
Change in professional duties
   Yes
   No
525 (60%)
344 (40%)








Nature of change in duties, n=579
   Scope of clinical work
        Direct patient care
        Remote consultations
        Inpatient work
        COVID-19 inpatient work
        Covering other oncology patients
        Covering non-oncology specialties
        Virtual MDT/tumour board meetings
        Remote meetings
   
   Working hours and shift patterns
        Overall hours of work
        Out-of-hours work in hospital
        Hours working from home
        Weekend shifts
        Overnight shifts
   Clinical trial and research activity
        Clinical trial activity
        Research (non-clinical trials) activity














































































   Yes 
   Partially 




Duration of redeployment, n=185
   <4 weeks
   1-3 months
   >3 months
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Table 3
Number (%)
Increased personal risk due to comorbidities or condition
   Yes
   No




Characteristics of comorbidities or condition
   Cardiac 
   Respiratory
   Diabetes mellitus
   Immunosuppressed
   Renal, Hepatic or Neurological
   Pregnant








Tested positive for COVID-19, n=484
   Yes
   No
39 (8.1%)
445 (91.9%)
Isolation or sick leave due to COVID-19 symptoms, n=39
   <2 weeks
   2-4 weeks
   >4 weeks
   No






Hospitalised for COVID-19, n=39
   <2 weeks
   2-4 weeks
   >4 weeks
   No






Median duration of symptomatic COVID-19, n=22 8.5 days (1-42)
Feel given appropriate time to recover, n=39
   Yes
   No




Feel completely recovered upon return to work, n=39
   Yes
   No




Had colleague who has died from COVID-19, n=849
   Yes
   No
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Table S1
Wellbeing support and coping strategies amongst participants during the COVID-19 crisis 
(n=942)
Number (%)
Access to wellbeing support services, n=942 421 (44.7%)
Wellbeing support services used, n=421
   Online or smartphone apps
   Spiritual or religious support
   Psychological support from work
   Personal psychiatrist or psychologist 
   Telephone support
   Charities supporting mental health 
   Psychological support from national organisations
   Other










Feeling well-supported during COVID-19, n=835
   By friends and/or family
   By colleagues at workplace
   By management of workplace
   By global or national societies







   By the public 
   By work organisation
537 (63.9%)
452 (53.7%)
Coping strategies used, n=942
   Thinking of positives 
   Change in physical activity (e.g. exercise)
   Talking to colleagues to get information
   Using humour, laughing
   Strategising and planning steps to take 
   Distracting myself
   Talking to colleagues to get emotional support
   Changing in diet (e.g. types of food, amount)
   Using meditation, mindfulness or other relaxation techniques
   Using religious or spiritual practice(s)
   Avoiding thinking about or not thinking about it
   Changes in substance intake (e.g. smoking, alcohol, others)
   Other
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HIGHLIGHTS 
 Four months into the COVID-19 pandemicCompared to Survey I1, more oncology 
professionals were at risk of poor well-being (33% vs 25%) and feeling burnout (49% 
vs 38%).
 Job performance since COVID-19 (JP-CV) has improved from 34% to 51%. 
 About one in five1 in 5 who tested positive for COVID-19 felt they had not been given 
adequate time to recover prior to return to work.
 39% expressed concerns that COVID-19 would have a negative impact on their career 
development or training.
 More than two-thirds revealed that COVID-19 had changed their outlook on work-
personal life balance. 
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ABSTRACT 
Background
The COVID-19 pandemic has resulted in significant changes to professional and personal lives 
of oncology professionals globally. The ESMO Resilience Task Force collaboration aimed to 
provide contemporaneous reports on the impact of COVID-19 on the lived experiences and 
well-being in oncology.
Methods
This online anonymous survey (July-August 2020) is the second of a series of global surveys 
launched during the course of the pandemic. Longitudinal key outcome measures including 
well-being/distress (expanded Well-being Index (eWBI – 9 items)), burnout (1 item from 
eWBI) and job performance since COVID-19 (JP-CV) were tracked.
Results
942 participants from 99 countries were included for final analysis: 58% (n=544) from Europe, 
52% (n=485) female, 43% (n=409) 40 years old, and 36% (n=343) of non-white ethnicity. In ≤
July/August 2020, 60% (n=525) continued to report a change in professional duties compared 
to pre-COVID-19 era. The proportion of participants at risk of poor well-being (33%, n=310) 
and reported feeling burnout (49%, n=460) had increased significantly compared to April/May 
2020 (25% and 38%, respectively; p<0.001), despite improved JP-CV (34% vs 51%; p<0.001). 
Of those who had been tested for COVID-19, 8% (n=39/484) tested positive; 18% (n=7/39) 
felt they had not been given adequate time to recover prior to return to work. Since the 
pandemic, 39% (n=353/908) had expressed concerns that COVID-19 would have a negative 
impact on their career development or training and 40% (n=366/917) felt that their job 
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security had been compromised. More than two-thirds (n=608/879) revealed that COVID-19 
has changed their outlook on their work-personal life balance. 
Conclusion
The COVID-19 pandemic continues to impact the well-being of oncology professionals globally 
with significantly more in distress and feeling burnout compared to the first wave. Collective 
efforts from both national and international communities addressing support and coping 
strategies will be crucial as we recover from the COVID-19 crisis. In particular, an action plan 
should also be devised to tackle concerns raised regarding the negative impact of COVID-19 
on career development, training, and job security.
Funding
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INTRODUCTION
The COVID-19 pandemic and our response to it continues to shape lives globally. Many 
healthcare workers have seen both their professional and personal lives significantly 
impacted, with the oncology community being no exception. The ESMO (European Society 
for Medical Oncology) Resilience Task Force, established in December 2019, launched a 
longitudinal series of global surveys in April/May 2020 (Survey I) and July/August 2020 (Survey 
II) to evaluate the challenges posed by COVID-19 on the daily practice and well-being of 
oncology professionals.1 Preliminary results from our survey series indicate that COVID-19 
has had a significant impact on the oncology workforce. Of the 1520 survey I participants, 
25% were at risk of distress, 38% reported feeling burnout, and 66% reported not being able 
to perform their job compared with the pre-COVID era.1 A higher mortality rate from COVID-
19 in individual countries correlated with poorer well-being. Individual psychological 
resilience and changes in work hours were also consistent predictors. This is in keeping with 
emerging trends in several studies reporting increased psychological distress and emotional 
exhaustion in other studies ofamongst healthcare workers, particularly with increased job 
demands, during this pandemic.2-5 Concerningly, amongst the 272 participants who 
completed both surveys I and II, a significant increase in risk of distress/poor well-being (22% 
versus 31%) and burnout (35% versus 49%) was already noted over a 3-month period during 
the pandemic despite improvements in job performance.1  
Here, we present the complete analysis of responses from all 942 participants of survey II of 
our global survey series.
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METHODS
Survey design
Survey II (open from 16 July to 5 August 2020) formed part of the series of online global 
surveys designed by the ESMO Resilience Task Force, in collaboration with ESMO Young 
Oncologists Committee, ESMO Women for Oncology Committee, ESMO Leaders Generation 
Programme Alumni members, and the OncoAlert Network. The programme of work including 
this current survey was approved by the ESMO Executive Board. Participants were invited 
predominantly through ESMO membership emails, and open access to the survey, hosted on 
the Qualtrics platform, was also available to both members and non-members through the 
ESMO website and social media channels. Participation was voluntary and anonymous.
Survey measures
Key outcomes of interest including well-being, burnout and job performance since COVID-19 
(JP-CV) were longitudinally monitored as per Survey I.1 In brief, a calculated cumulative score 
of ≥4 on the validated expanded Well-being Index (eWBI) 9-item screening tool is considered 
at risk of poor well-being or distress.6 A ‘yes’ response to th  single item from eWBI,1,7 ‘have 
you felt burned out from your work?’ was used as a surrogate for self-reported burnout 
amongst participants. JP-CV score of ≥3.5 was arbitrarily categorised as favourable JP-CV.1   
In addition, psychological resilience (single item 9-point bipolar scale, C. Hardy (unpublished 
data)), coping strategies, COVID-19-related job changes, perceptions of value and support, 
working environment, and changes to lifestyle were recorded. We also included 
contemporaneous questions relevant to participants’ experiences during this period of the 
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pandemic such as personal experience of COVID-19, perceptions of their career development 
and/or training and job security, and general outlook in life.
Statistical analysis
Key outcome variables including eWBI, burnout, JP-CV and psychological resilience were 
longitudinally compared to the results from Survey 11 to determine any changes over time. 
Descriptive data were presented as median (interquartile range, IQR) or mean±standard 
deviation (SD), and proportions were expressed as a percentage. Chi-square analysis was 
used to compare categorical variables and paired or unpaired t-test were used to analyse 
continuous variables; p-values were two-tailed and were considered significant if <0.05. 
Participants who completed 33% of the survey (completion of survey beyond personal ≥
demographic profile and with the four key outcome variables above recorded) were included 
in the final analysis. All statistical analyses were performed using SPSS V.26.0 and data 
represented using GraphPad Prism V9.0. 
RESULTS
Participant demographics
A total of 942 participants from 99 countries who completed 33% of the online survey ≥
(n=816 (86.6%) with 100% completion) were included in the final analysis. By July/August 
2020, most participants (n=826, 87.7%) had experienced some form of lockdown/restriction 
in their region of work and only a minority (n=44, 4.7%) were working in a ‘COVID-19-free’ 
country. Table 1 summarises the key demographic characteristics of the participants.
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During the time of Survey II, responses were predominantly from Europe (n=544, 57.7%) with 
the highest representation from those working in medical oncology (n=634, 67.3%) and those 
working in a general hospital (n=421, 44.1%) or tertiary cancer centre (n=368, 39.1%) (Table 
1). More than half of the participants were female (n=485, 51.5%), over 40 years old (n=533, 
56.6%), and of white ethnicity (n=587, 62.3%) (Table 1). About 1 in 5 (n=184) were trainees, 
and amongst those who were fully-trained oncologists, majority (n=437, 57.7%) had more 
than 10 years of experience in the field (Table 1).
Changes in professional duties since COVID-19
In July/August 2020, the majority of participants (n=525/869, 60.4%) were still reporting a 
change in their professional duties when compared to pre-COVID-19 era. The nature of 
changes in professional duties are outlined in Table 2. There was a marked increase in remote 
consultations (n=472/528, 89.4%), virtual multidisciplinary team/tumour board meetings 
(n=450/534, 84.3%), remote meetings (n=506/550, 92.0%), and COVID-19-related research 
activity (n=202/344, 58.7%) (Table 2). In particular, more than a third (n=221/575, 38.4%) had 
reported an increase in overall hours of work in comparison to pre-COVID-19 work schedule 
and about two-thirds (n=362/549, 65.9%) had reported an increase in hours working from 
home (Table 2 and Supplementary Figure S1). The majority were still experiencing a reduction 
in clinical trials (n=320/486, 65.8%) and other research (n=275/493, 55.8%) activities (Table 
2). Overall, however, the self-reported job performance since COVID-19 (JP-CV) had increased 
compared to April/May 2020; the proportion of those with JP-CV score ≥3.5 had increased 
from 34.4% (n=523/1520) to 50.9% (n=444/873) in July/August 2020, p<0.001.
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Personal experience of COVID-19
More than 1 in 5 participants (n=181/854, 21.2%) disclosed that their current circumstance 
or underlying comorbidities would put them at an increased personal risk of being seriously 
ill from COVID-19 (Table 3). Amongst those who had been tested (n=484), 39 participants 
(8.1%) had had COVID-19. Most underwent isolation or sick leave due to COVID-19 symptoms 
(n=25/39, 64.1%). Within this subgroup who had had COVID-19, the median duration of 
symptomatic COVID-19 was 8.5 days (n=22, range 1 to 42 days). About 1 in 5 (n=7/39) did not 
feel they were given appropriate time to recover and 11 participants (28.2%) did not feel 
completely recovered upon return to work. Notably, 14.8% (n=126/849) revealed that they 
have had a colleague who has died from COVID-19. 
The impact of COVID-19 on perception of career development and training
As the COVID-19 pandemic evolved, we questioned participants regarding their outlook in 
their personal and professional life. Alarmingly, 38.9% (n=353/908) had expressed concerns 
that the pandemic would have a negative impact on their career development and/or 
training, and 39.9% (n=366/917) felt that COVID-19 has negatively impacted on their job 
security (Figure 1a-1b). Majority (n=650/861, 75.5%) were also concerned about the negative 
impact on international fellowship opportunities (Figure 1c). 
The feeling of loss of control and helplessness during the COVID-19 crisis
During the course of the COVID-19 pandemic, more than a third of participants (n=339/859, 
37.5%) had experienced a loss of control or felt helpless in meeting the expectations of their 
patients (Figure 1d). Similarly, more than a quarter also expressed the perception of loss of 
control or helplessness in meeting the expectations of their colleagues, supervisor and/or 
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employer (Figure 1d). Additionally, more than half feeling loss of control or helpless with 
regards to pursuing their career goal (n=458/866, 52.9%) (Figure 1e).
On personal reflection, for more than two-thirds of participants (n=608/879, 69.2%), the 
COVID-19 pandemic had changed their outlook on work-personal life balance (Figure 1f). A 
majority (n=612/870, 70.3%) would like to dedicate more time to their personal life, however 
only less than a third (n=271/863, 31.4%) felt that a change in their work-personal life balance 
could be easily achievable (Figure 1f). Currently, 43.0% (n=405/942) of participants did not 
feel that their work schedule leaves them enough time for their personal and family life.
Well-being and burnout
Among participants, 32.9% (n=310) were at risk of poor well-being (eWBI score ≥4) and 48.8% 
(n=460) reported feeling burnout compared to 25% (p<0.001) and 38% (p<0.001) of the 1520 
participants surveyed in April/May 2020, respectively. The magnitude of increase in both of 
these outcome measures were also seen within the subgroup of 272 participants who 
responded to both Surveys I and II.1
Resilience, well-being support and coping strategies
Collectively, there was no difference in psychological resilience amongst participants in both 
Surveys I and II: mean score 6.4±1.9 versus 6.4±2.0, respectively (p=0.82). Access to well-
being support services was available to less than half of the participants (n=421, 44.7%). 
Supplementary Table S1 summarises a variety of well-being support services and coping 
strategies commonly used by participants during this COVID-19 pandemic. Importantly, 
majority continued to feel well-supported by their friends and/or family (n=729/835, 87.3%) 
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and by their colleagues at work (n=648/835, 77.6%). In Survey II, 63.9% (n=537/841) and 
53.7% (n=452/841) expressed feeling valued by the public and their work organisation, 
respectively.
DISCUSSION
Within a three-month period (April/May 2020 to July/August 2020) at the beginning phase of 
the COVID-19 pandemic, Survey II has already highlighted a significant increase in risk of poor 
well-being (33% versus 25%) and burnout (49% versus 38%). This is despite significant 
improvement in self-reported job performance over the same timeframe time period. This is 
an alarming finding and suggests that although oncology professionals may be adapting 
effectively to change, they continue to be at increasing risk of distress.  
Survey II highlights a number of factors in the current climate that may be contributing to this 
deterioration in well-being. Most participants (n=826, 88%) had experienced some form of 
lockdown/restriction in their region of work. In addition to such significant imposed changes 
in their personal lives, around 60% of participants continued to report a change in 
professional duties. Some of these, such as an increase in remote consultations and virtual 
meetings, have their advantages.4,8 However, nearly 40% had reported an overall increase in 
their work hours compared to their pre-COVID-19 schedule (also see supplementary Figure 
S1). The majority had also experienced a reduction in clinical trials and traditional oncology-
focused research activity. These are an integral part of working life in oncology and often a 
source of meaning. Increased working hours and a reduction in activities that are 
professionally meaningful are well-known risk factors for burnout.9  
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More Survey II participants had reported a close personal experience with COVID-19 either 
by testing positive for SARS-CoV-2 (8%) or requiring self-isolation or sick leave due to COVID-
19 symptoms (18%). Worryingly, nearly 15% had had a colleague die from COVID-19. 
Furthermore, one in five participants also disclosed that they had underlying comorbidities 
that would put them at an increased personal risk of being seriously ill from COVID-19. Of 
those who have had COVID-19, the median duration of symptomatic COVID-19 was 8.5 days 
but notably, the range for this was broad, from 1 to 42 days. Importantly, 18% feel that they 
did not have enough time to recover from illness and close to 30% did not feel completely 
recovered from illness prior to returning to work. Given the reports of potential substantial 
long-term morbidity associated with COVID-19 (‘long COVID’),10,11 this is particular cause for 
concern and will require careful ongoing monitoring.  
A substantial number of participants had expressed significant uncertainty about the future 
of their professional lives. Approximately 40% felt that COVID-19 would have a negative 
impact on their career development, training, and job security. Over 75% were also concerned 
about the negative impact on international fellowship opportunities, an important facet of 
professional development in oncology. This ties in with a recurrent concern expressed by 
participants of loss of control or helplessness in achieving their career goals (53%).  
Anxiety and fear amongst healthcare workers can be associated with higher rates of burnout.4  
Delays in patient care and treatment have been a substantial source of distress in other 
studies for oncology practitioners.4 These are understandable responses in a climate of crisis 
and prolonged uncertainty as has been noted during previous pandemics.3 Overall, our 
findings highlight significantly increasing rates of distress and burnout. The rapidity in the 
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rates of increased burnout distress within a three-month period is a notable finding and a 
major cause for concern. This may be an ominous harbinger of what lies ahead in ongoing 
and future ESMO Resilience Task Force surveys which have coincided with periods of 
extended lockdown and further ‘waves’ of cases and deaths. The time for action therefore is 
now. Survey II already highlights useful areas of support and immediate intervention that may 
be of benefit to oncology professionals globally.
Firstly, there are significant measures organisations can take to improve the well-being of 
staff. Enhanced mentorship of practitioners to ensure ongoing support for career 
development and planning as well as sourcing of suitable professional opportunities. Despite 
the focus on the COVID-19 response, ongoing investment in oncology-focused research and 
clinical trials need to continue, including fostering transnational fellowship opportunities.12-14 
More particularly, despite additional pressures, the accessible and continued support of 
supervisors for trainees is even more paramount. A routinely scheduled time for a “team 
huddle” or debriefing program for all staff in the emergency department has been shown to 
be well-received and beneficial for both junior and senior team members alike during these 
challenging times.15
Secondly, the personal impact of COVID-19 on the health and well-being of oncology 
professionals have been emphasised by the findings of Survey II. Ensuring safe work 
conditions, including access to personal protective equipment, COVID-19 testing, and 
vaccination are paramount.16,17 Also ensuring the provision of adequate sick leave for self-
isolation and recovery from symptoms should be mandated, as well as, supporting “shielding” 
practices to ensure those with comorbidities are in lower risk activities or exposure sites. The 
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number of participants who had experienced the death of a colleague also raises the need for 
adequate access to bereavement support. Participants had similarly highlighted that access 
to counselling/psychological services and other resources to promote well-being and coping 
strategies would be welcomed.  
Of importance for future oncology workforce planning, the majority of participants had 
reported changing their outlook on their work-personal life balance as a result of the COVID-
19 pandemic, including a desire for better work-life balance. The majority supported flexible 
working hours, including working from home. Ensuring work hours and workplace flexibility 
as well as encouraging staff to take annual leave are important organisational leadership 
measures.
Although we focus on the solutions necessary, participants had likewise shared a number of 
strategies they were already using to cope currently, such as tapping into personal and 
professional support networks, employing strategies such as mindfulness meditation and 
smartphone apps, and feeling valued by their organisation. Supportive interventions need to 
be multi-faceted with workplaces, and national and international oncology societies such as 
ESMO and American Society of Clinical Oncology (ASCO)18 playing a key facilitative role.
A significant strength of Survey II is our substantial participant size of 942 and scope with 99 
countries being represented. Over a third of our participants were from Germany, India, 
United Kingdom, Italy, Spain and Brazil – a number of these countries have borne the brunt 
of global morbidity and mortality, which makes their representation in this survey important 
and notable. There was even representation across the genders (52% female), as well as 
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young oncologists (43%), current trainees (20%), and those of non-white ethnicity (36%), as 
our previous research and that of other groups have found these groups to be at particularly 
heightened risk of experiencing burnout.1,19,20 More than a third of participants were of non-
white ethnicity, which is again an important aspect as studies have shown that those of black 
or minority ethnic backgrounds are at higher risk of complications from COVID-19.21  
A key factor in the well-being of all during these times has been the response of individual 
nations to this pandemic. Only a small minority of participants in our survey (4%) were from 
‘COVID-19-free’ nations which reflects their smaller population size. Our ability to discern the 
difference in well-being between those in higher prevalence versus COVID-19-free regions 
has been limited by this small sample size. This is also a cross-sectional, observational study 
which limits our ability to infer causality. However, to our knowledge, this is the only survey 
series in oncology addressing well-being systematically and longitudinally throughout the 
course of the COVID-19 pandemic. A substantially larger dataset from the recently closed 
Survey III and more detailed longitudinal statistical analyses of factors associated with well-
being, burnout and distress will provide further insight into navigating recovery plans going 
forwards. The collective experience shared by participants completing this survey series, and 
the ongoing work of the ESMO Resilience Taskforce and other organisations will help direct 
efforts to support the well-being of oncology professionals globally.
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TABLE CAPTIONS 
Table 1 Participant demographics (n=942).
Table 2 Overview of the changes in professional duties since the COVID-19 outbreak 
(n=942).
Table 3 Participants’ personal experience of COVID-19 (n=854)
FIGURE CAPTIONS 
Figure 1 The impact of COVID-19 on (a- c) the perception of career development and/or 
training opportunities (n=925), (d-e) sense of control (n=892), and (f) future 
outlook in work/personal life balance (n=892).
Figure 2 Summary of key suggestions from participants on well-being and coping 
strategies which might be helpful as part of the COVID-19 recovery plan 
(n=827). 
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SUPPLEMENTARY DATA
Table S1 Well-being support and coping strategies amongst participants during the 
COVID-19 crisis (n=942).
Figure S1 Comparison of self-reported working hours amongst participants during 
Survey I (16 April to 3 May 2020) (n=1520) and Survey II (16 July to 5 August 
2020) (n=872).
Figure S2 Working environment during the COVID-19 pandemic in July/August 2020 
(n=846).
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